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Abstract 
MicroRNAs (miRNAs) are a class of short (~22nt), single stranded RNA molecules that function as 
post-transcriptional regulators of gene expression. MiRNAs can regulate a variety of important 
biological pathways, including: cellular proliferation, differentiation and apoptosis. Profiling of 
miRNA expression patterns was shown to be more useful than the equivalent mRNA profiles for 
characterizing poorly differentiated tumours. As such, miRNA expression “signatures” are ex-
pected to offer serious potential for diagnosing and prognosing cancers of any provenance. The 
aim of this study was to investigate the potential of using deregulation of urinary miRNAs in order 
to detect Prostate Cancer (PCa) among Benign Prostatic Hyperplasia (BPH). To identify the 
miRNA signatures specific for PCa, miRNA expression profiling of 8 PCa patients, 12 BPH patients 
and 10 healthy males was carried out using whole genome expression profiling. Differential ex-
pression of two individual miRNAs between healthy males and BPH patients was detected and 
found to possibly target genes related to PCa development and progression. The sensitivity and 
specificity of miR-1825 for detecting PCa among BPH individuals was found to be 60% and 69%, 
respectively. Whereas, the sensitivity and specificity of miR-484 were 80% and 19%, respectively. 
Additionally, the sensitivity and specificity for miR-1825/484 in tandem were 45% and 75%, re-
spectively. The proposed PCa miRNA signatures may therefore be of great value for the accurate 
diagnosis of PCa and BPH. This exploratory study has identified several possible targets that merit 
further investigation towards the development and validation of diagnostically useful, non-invasive, 
urine-based tests that might not only help diagnose PCa but also possibly help differentiate it from 
BPH. 
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Introduction 
Globally, PCa is the second most common, 
non-cutaneous cancer among men (1, 2). Various 
studies have observed a positive correlation between 
age and incidence of PCa (2, 3, 4). Environmental 
factors, particularly diet, have also been reported to 
potentially play a role in a man’s risk for PCa (5). A 
number of techniques are currently available for as-
sessing prostate health, the most common of which 
include digital rectal exam (DRE), trans-rectal ultra-
sonography (TRUS), and prostate specific anti-
gen-based testing (PSA) (6, 7).  
Since PSA is primarily produced in the prostate 
and is therefore relatively prostate specific, it was 
proposed that a sharp but consistent increase in serum 
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PSA was indicative of exponential prostate cell 
growth, as might occur in PCa (8). PSA test had been 
validated for detecting PCa using any serum level 
above the empirically determined cutoff of 4ng/mL 
(9). PSA’s use as a marker for PCa was soon limited by 
the many instances of BPH that were also associated 
with an increased serum PSA above the 4ng/mL cut-
off, and especially in the range of 4-10ng/mL (10).  
Serum PSA testing for the early detection of PCa 
has a sensitivity of around 86% and a specificity of 
approximately 33%, depending on patient's age and 
local prevalence of disease (11, 12). These problems 
have formed the basis for much controversy sur-
rounding PSA’s use as a regular blood-based screen-
ing tool for PCa (13, 14). As such, the search for novel 
PCa biomarkers, especially from non-invasive fluids, 
has been ongoing (15, 16). 
MicroRNAs (miRNAs) are a class of short 
(~22nt), single stranded RNA molecules that function 
as post-transcriptional regulators of gene expression 
(17). MiRNAs have been found to play a significant 
role in carcinogenesis (18). They do so via their ability 
to function as regulators of tumour suppressors and 
oncogenes (19). MiRNA expression “signatures” are 
expected to offer serious potential for diagnosing and 
prognosing cancers of any provenance (20, 21). 
Oncomirs, as they are known, function to 
down-regulate traditional tumour suppressor genes. 
An over-abundance of such microRNAs has been im-
plicated in the progression of certain cancers (22). For 
example, PTEN, a tumour-suppressor gene that is 
responsible for promoting apoptosis via the 
PI3K-AKT-mTOR pathway, is a predicted target of 
microRNAs belonging to the miR-17–92 cluster (23, 
24). While miRNAs such as those in the 17-92 cluster 
have been observed functioning as oncogenes, other 
miRNAs such as let-7 have been observed acting like 
tumour suppressors (22). MiRNAs that function as 
tumour suppressors do so by targeting traditional 
oncogenes, i.e. genes that promote cellular prolifera-
tion or that block apoptosis. For example, a number of 
human cancers have been shown to harbour a dele-
tion in the chromosomal region encoding the let-7 
microRNA (25). In particular, down-regulation of 
let-7 has been observed in several human lung cancers 
(26).  
While differences in methodology and sampling 
likely form the basis for such inconsistencies, it’s 
through studies like these that an association between 
PCa and several miRNAs has already been tentatively 
established (27). To date however, no miRNA-based 
diagnostic test has yet been approved for the early 
detection of PCa. In this study, the miRNA expression 
profiles in urine samples collected from PCa patients, 
BPH patients as well as from healthy male group were 
analyzed. MiRNA profiling was firstly carried out on 
miRNA isolated from urine samples pooled from each 
group using LC Sciences patented microarray tech-
nology. Furthermore, we evaluated the deregulation 
of 2 miRNAs, revealed from our data, as potential 
non-invasive urinary biomarkers for the accurate di-
agnosis of prostate cancer among Benign Prostatic 
Hyperplasia Patients. 
Materials and Methods 
Urine sample collection.  
After approval from the Research Ethics Board at 
Brock University (St. Catharines, ON, Canada), urine 
samples were collected from 29 Egyptian males pre-
sent at Alexandria University’s General Hospital 
(Alexandria, Egypt). Urine samples were collected 
into 50mL Corning tubes containing Norgen’s Urine 
Preservative Solution (Cat# 18126) (Norgen Biotek, 
Thorold, ON, Canada). The samples were acquired 
from among three groups of individuals, each de-
scribed by a questionnaire completed by the patients’ 
attending physician. Group I urine samples were col-
lected from eight individuals diagnosed with Prostate 
Cancer (PCa). Group II urine samples were collected 
from twelve individuals with Benign Prostatic Hy-
perplasia (BPH). Urine samples from Group III were 
collected from ten healthy males (Table 1). Urine 
samples collected from men with other ailments, in-
cluding Diabetes mellitus, kidney disease, and/or 
infections such as chronic HBV, HBV/HCV 
co-infection or Schistosomiasis, were excluded from 
participation. Each man included in the study was 
also given a PSA test as part of sample collection. 
Furthermore, urine samples were collected from the 
same patients two years from their initial participa-
tion in the study; a PSA test was also performed for 
this second collection. 
 
Table 1. Clinical parameters regarding the males involved with this study. 
 Healthy 
Males 
Prostate 
Cancer Pa-
tients 
Benign Prostatic 
Hyperplasia 
Patients 
Number of males 10 8 12 
PSA Level (ng/mL) (0.8 ± 0.6) (7.9 ± 3.0) (4.9 ± 1.4) 
HCV or HBV Status -Ve -Ve -Ve 
Diabetes mellitus -Ve -Ve -Ve 
Schistosomiasis -Ve -Ve -Ve 
Kidney diseases -Ve -Ve -Ve 
 
Isolation of total RNA from urine.  
Total RNA was isolated from 2.5mL of urine 
using the Urine Total RNA Purification Maxi Kit 
(Slurry Format) (Cat# 29600) (Norgen Biotek, 
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Thorold, ON, Canada). The isolation was performed 
according to the manufacturer’s instructions.  
MicroArray-based MicroRNA Expression 
Profiling in Pooled Samples.  
Differential expression analysis of miRNAs be-
tween the pooled samples was performed using LC 
Science’s μParaflo™ MiRNA Microarray technology.  
Relative expression profiling for candidate 
miRNAs using RT-qPCR.  
Relative miRNA expression levels for the 5 can-
didate miRNAs (miR-1234, miR-1238, miR-1913, 
miR-486-5p, miR-1825, miR-484 and miR-483-5p) 
were analyzed among the PCa group, BPH group and 
the healthy male group. Candidate miRNAs were 
reversibly-transcribed using 3µl of RNA template and 
0.5µl gene-specific stem-loop RT primer (Table 2). The 
reaction was then made up with RNase-free water to 
10μL and incubated for 5 mins at 70°C and was then 
held at 4ºC. During the 4°C incubation, a mix of 4µl 5X 
first strand Buffer, 2µl of 0.1mM DTT, 1µl of 10mM 
dNTPs, 0.5µl SuperScript III (Invitrogen) and 2.5µl 
nuclease-free water were added to the initial reaction 
for a final reaction volume of 20µL. The final reaction 
was then incubated at 25°C for 5 min, 50°C for 30 min, 
70°C for 15 min with a final hold at 4°C. For controls, 
minus All samples were analyzed using the iCycler iQ 
real time PCR detection system with iQ SYBR Green 
Supermix (BioRad Laboratories). For each sample, 3μl 
from its corresponding RT reaction were mixed in a 
10μl iQ SYBR Green Supermix, 6.76μl nuclease-free 
water and 0.12μl each specific forward and reverse 
miRNA primer (Table 2) in a total of 20μl. The ex-
pression levels were normalized to 5S rRNA levels. 
Relative gene expression was expressed as the LOG2 
of fold change. Fold changes were calculated using 
the ΔΔCt method (28). 
Results 
MicroArray-based MicroRNA Expression 
Profiling in Pooled Samples 
Total RNA was isolated from 2.5mL of each 
urine sample using the Urine Total RNA Purification 
Maxi Kit (Slurry Format, Cat# 29600; Norgen Biotek, 
Thorold, ON, Canada). Purified RNA from each 
sample within a group was then pooled, resulting in 
three samples: PCa, BPH and Healthy Control. Dif-
ferential expression analysis of miRNAs between the 
pooled samples was performed using LC Science’s 
μParaflo™ MiRNA Microarray technology. To de-
termine fold change, the signal intensity of each 
miRNA (in pooled PCa or BPH) was divided against 
the corresponding miRNA level for the healthy con-
trol group and the LOG2 of the quotient was then ob-
tained. 
 
Table 2. Synthetic oligonucleotides used in this study. 
Name Sequence 
5S rRNA (Forward) 5'GCCATACCACCCTGAACG3' 
5S rRNA (Reverse) 5'AGCCTACAGCACCCGGTATT3' 
SL-miR-486-5p 5'GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACCTCGG3' 
miR-486-5p (Forward) 5'TCCTGTACTGAGCTGCC3' 
SL-miR-1825 5'GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACGGAGA3' 
miR-1825 (Forward) 5'TCCAGTGCCCTCCTCT3' 
SL-miR-484 5'GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACATCGG3' 
miR-484 (Forward) 5'TCAGGCTCAGTCCCCTC3' 
SL-miR-1238 5'GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACGGGGC3' 
miR-1238 (Forward) 5'CTTCCTCGTCTGTCT3' 
SL-miR-1913 5'GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACTGGCA3' 
miR-1913 (Forward) 5'TCTGCCCCCTCCGCTGC3' 
SL-miR-1234 5'GTCGTATCCAGTGCAGGGTCCGAGG
TATTCGCACTGGATACGACGTGGG3' 
miR-1234 (Forward) 5'TCGGCCTGACCACCCAC3' 
 
 
Of the 894 miRNAs assayed, seventeen were 
found to differ significantly in their levels between the 
three groups (ANOVA p-value < 0.01). These 
miRNAs included: miR-1826, miR-1234, miR-1238, 
miR-191*, miR-484, miR-191, miR-451, miR-486-5p, 
miR-1913, miR-625*, miR-1825, miR-92a, miR-92b, 
miR-483-5p, miR-486-3p, miR-563, miR-940 (Figure 1). 
Of these seventeen, all but miR-483-5p was 
down-regulated in PCa with respect to the healthy 
control group. Similarly in BPH, miR-1826 were both 
found to be up-regulated, and the rest 
down-regulated with respect to the healthy control 
group. From the microarray results: each of the sev-
enteen miRNAs except for miR-1826, were deregu-
lated in the same direction in both PCa and BPH 
(when each pool was compared to the healthy control 
pool).  
From these seventeen, only certain miRNAs 
were selected for further analysis. Based on published 
literature suggesting that a miRNA’s mRNA target 
was potentially involved in cancer (targets deter-
mined using TargetScan and MiRanda databases as 
outlined by Griffiths-Jones et al. in 2006) (29), seven of 
miRNAs were selected for further expression analysis 
among individual urine samples. The selected miR-
NAs included miRs: 1234, 1238, 1913, 486-5p, 1825, 
484 and 483-5p. Their putative mRNA targets and the 
literature proposing each target’s potential role in 
cancer are summarized in Table 3.  
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Validation of MicroRNA Deregulation among 
Individual Prostate Cancer Samples using 
RT-qPCR 
Seven of the selected miRNAs were, according to 
microarray data on pooled samples, deregulated in 
PCa with respect to the healthy control group. In or-
der to evaluate those miRNA’s potential as candidate 
biomarkers for PCa, the relative expression of each 
was examined in all individual PCa samples by using 
RT-qPCR. To allow for a comparison of expression 
levels between samples, the expression of each 
miRNA was normalized against each sample’s own 
content of 5S ribosomal RNA. Relative expression 
between each PCa sample and the average expression 
of the healthy control group was then calculated as 
LOG2 fold change values using the following equa-
tion: LOG2 (2-∆Ct (target miRNA) PCa / 2-∆Ct (target miRNA) 
Healthy Control). For PCR data, an absolute LOG2 
value of one or more was considered deregulated, 
while a value of less than one was considered mini-
mally deregulated / unchanged. Table 4 lists the rela-
tive expression of each of the seven miRNAs, for each 
of the initially collected PCa samples and with respect 
to the average expression of the healthy control 
group. 
Interestingly a substantial majority of PCa sam-
ples expressed the same type of deregulation for a 
miRNA: miR-1825 and miR-484. MiR-1825 was 
up-regulated in seven out of eight PCa samples (88%); 
furthermore in the eighth PCa sample miR-1825 ex-
pression was unchanged with respect to healthy. PCR 
results showed that miR-484 was down-regulated in 
six out of the eight PCa samples (75%), up-regulated 
in one and unchanged in another. Figure 2 illustrates 
these percentages visually.  
 
 
 
Figure 1. Expression of Eighteen Significantly Deregulated MiRNAs 
between Pooled PCa, BPH and Healthy by Microarray. 
 
 
 
Table 3. Selected microRNAs and their Putative Targets. 
MicroRNA Type of Deregulation Putative Target Reference 
miR-1234 Down in PCa & BPH vs Healthy DAB2-Interacting-Protein 30, 32, 33 
miR-1238 Down in PCa & BPH vs Healthy SASH1 (SAM & SH3 domain containing protein 1) 33 
miR-1913 Down in PCa vs BPH vs Healthy HSPG2 (heparan sulphate proteoglycan 2) 34 
miR-486-5p Down in PCa vs BPH vs Healthy CD40 (tumour necrosis factor receptor) 35 
miR-1825 Down in PCa vs BPH vs Healthy DDR1 (discoidin domain receptor tyrosine kinase 1) 36, 37, 38 
miR-484 Down in PCa vs BPH vs Healthy UBR5 (ubiquitin protein ligase E3 component n-recognin 5) 39 
miR-483-5p Up in PCa vs BPH & Healthy Selenoprotein O 40 
 
Table 4. LOG2 fold change in the expression of the 7 miRNA among PCa patients relative to average healthy expression. (Red – Two fold or more 
up-regulated, Green – Two fold or more down-regulated, and Black – Minimally Deregulated / Unchanged). 
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Figure 2. Percentage of the Initial PCa Samples with two fold or more deregulation of a microRNA. 
 
Screening for Deregulation of miR-1825 and 
miR-484 in BPH Samples by RT-qPCR 
Since only miR-1825 and miR-484 showed con-
sistent up- and down-regulation across a majority of 
PCa samples by PCR (88% and 75%, respectively), 
they were selected for further evaluation among BPH 
samples; a group of patients who are usually falsely 
identified as having PCa by PSA testing. Table 5 dis-
plays the LOG2 fold changes for the expression of 
miR-1825 and miR-484 among the initially collected 
BPH samples with respect to the average expression 
in the healthy control group. MiR-1825 was found to 
have variable expression between BPH samples. In 
particular miR-1825 was found to be up-regulated in 4 
of the 12 samples or 33% of them, minimally deregu-
lated or unchanged in 6 (50%) and down-regulated in 
2 (17%). MiR-484 on the other hand was found to be 
two or more fold down-regulated in all of the initially 
collected BPH samples (100%). Figure 3 illustrates the 
percentage of initially collected BPH samples with 
up-regulation or miR-1825 and down-regulation of 
miR-484. 
Table 5. LOG2 fold changes of the expression of miR-1825 & miR-484 
among BPH patients relative to average healthy expression. (Red – Two 
fold or more up-regulated, Green – Two fold or more down-regulated, 
and Black – Minimally Deregulated). 
 
 
 
 
Figure 3. Percentage of BPH patients with two or more fold deregulation 
of miR-1825 or miR-484. (Red – Two fold or more up-regulated, Green – 
Two fold or more down-regulated). 
 
Screening for the Status of miR-1825 and 
miR-484 in PCa Patients: Two Years Later 
In order to validate the initial findings, miR-1825 
and miR-484 were assessed for up- and 
down-regulation in urine samples that were collected 
two years from the initial collection and from the 
same individual PCa patients. Again, relative expres-
sion was examined by RT-qPCR and both transcripts 
were normalized against the intrinsic 5S-rRNA pre-
sent in each sample. Relative expression between 
samples was then calculated as LOG2 fold change 
values according to the following equation: LOG2 
(2-∆Ct (target miRNA) PCa / 2-∆Ct (target miRNA) Healthy Con-
trol). Table 6 lists the LOG2 fold change between each 
PCa sample that was collected after two years and the 
average for the original healthy control group, for 
both miR-1825 and miR-484. While miR-1825 was 
initially found to be two or more fold up-regulated in 
88% of the PCa samples, after two years it was only 
up-regulated among 50% of them or in four of the 
eight. MiR-484 meanwhile, while initially found to be 
down-regulated in 75% of PCa samples, was after two 
years down-regulated in 88% of them or in seven out 
of eight. Figure 4 illustrates the percentage of PCa 
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patients with up- and down-regulation of miR-1825 
and miR-484 at each time point.  
Screening for the Status of miR-1825 and 
miR-484 in BPH Patients: Two Years Later 
Since up- and down-regulation of miR-1825 and 
miR-484 was common to urine samples collected from 
individuals with PCa, including samples collected 
from the same cohort two years later, it was decided 
to assay their expression in BPH samples collected 
two years later, again by RT-qPCR. It should be noted 
that upon follow-up, only eight of the original twelve 
BPH patients participated. Table 7 lists the LOG2 fold 
change values for miR-1825 and miR-484 in the BPH 
samples that were collected after two years; expres-
sion is relative to the average expression of the 
healthy control group. MiR-1825 was found to be two 
or more fold up-regulated in two of the eight BPH 
samples or 25% of them, down from 33% previously. 
MiR-484 was found to be two or more fold 
down-regulated in four of the eight BPH patients 
(50%), down from 100% observed two years prior. 
Figure 5 illustrates the percentage of BPH patients 
with up- and down-regulation of miR-1825 and 
miR-484 at both time points. 
 
 
Table 6. LOG2 fold changes of the expression of miR-1825 & miR-484 
among PCa patients relative to average healthy expression after two years. 
(Red – Two fold or more up-regulated, Green – Two fold or more 
down-regulated, and Black – Minimally Deregulated). 
 
 
 
Table 7. LOG2 fold changes of the expression of miR-1825 & miR-484 
among BPH patients relative to average healthy expression after two years. 
(Red – Two fold or more up-regulated, Green – Two fold or more 
down-regulated, and Black – Minimally Deregulated). 
 
 
 
 
Figure 4. Percentage of PCa Patients with deregulation of miR-1825 or miR-484, initially and after two years. (Red – Two fold or more up-regulated, 
Green – Two fold or more down-regulated). 
 
 
Figure 5. Percentage of BPH patients with two or more fold deregulation of miR-1825 or miR-484; both initially and after two years. (Red – Two fold or 
more up-regulated, Green – Two fold or more down-regulated). 
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Diagnostic Utility of miR-1825 and miR-484 for 
Diagnosing Prostate Cancer  
To evaluate the potential of using aberrant ex-
pression of miR-1825 or miR-484 for diagnosing PCa 
the medical records, specifically PSA values and clin-
ical diagnoses, were updated for all BPH patients as 
part of the two-year follow-up. It should be noted that 
all BPH patients were as a result diagnosed twice, 
both initially and after two years. Interestingly, dur-
ing their second assessment it was discovered that 
four of the BPH patients had PCa (Table 8).  
By comparing putative diagnoses (of PCa) made 
using miRNA deregulation against the actual clinical 
diagnoses, the sensitivity and specificity for using 
miR-1825 up-regulation and miR-484 
down-regulation (either separately or in tandem) for 
diagnosing PCa were determined. The following cri-
teria were applied: patients with a positive clinical 
diagnosis and exhibiting deregulation of either 
miR-1825 or miR-484 or deregulation of both were 
considered true positives; patients with a positive 
diagnosis and not exhibiting deregulation of any of 
the miRNAs (either separately or in tandem) were 
considered false negatives; patients with a negative 
diagnosis and exhibiting deregulation of either 
miR-1825, miR-484 or deregulation of both were con-
sidered false positives; and finally, patients with a 
negative diagnosis and not exhibiting deregulation of 
either miR-1825 or miR-1825 or deregulation of both, 
were considered true negatives.  
The above-mentioned criteria were applied to 
each sample that had a clinical diagnosis (including 
PCa samples), yielding the sensitivity and specificity 
values for diagnosing PCa. Using miR-1825 to diag-
nose PCa resulted in a sensitivity of 60% and a speci-
ficity of 69%, while using miR-484 to diagnose PCa 
resulted in a sensitivity of 80% and a specificity of 
19%. Additionally, the sensitivity and specificity of 
using tandem deregulation of both microRNAs at the 
same time was 45% and 75%, respectively. Further-
more, the sensitivity and specificity of a panel, em-
ploying deregulation of both microRNAs as well as an 
abnormal PSA value (more than or equal to 4ng/mL) 
for detecting PCa was 40% and 81% respectively. Ta-
ble 9 summarizes the sensitivity and specificity values 
for the various targets. 
 
Table 8. Diagnosing PCa by Assessing Deregulation of miR-1825 or miR-484 among BPH Samples. 
 Initial Urine Collection Urine Collection After 2 Years 
Test Result for PCa Clinical Diag-
nosis for PCa 
Serum PSA 
Levels 
(ng/mL) 
Test Result for PCa Clinical Diag-
nosis for PCa 
Serum PSA 
Levels 
(ng/mL) 
miR-1825 miR-484 miR-1825 miR-484 
BPH1 PCa PCa Healthy 4.3 Healthy PCa PCa 3.9 
BPH2 PCa PCa Healthy 5.6 N/A N/A N/A N/A 
BPH3 Healthy PCa Healthy 3.9 N/A N/A N/A N/A 
BPH4 Healthy PCa Healthy 5.8 Healthy Healthy Healthy 9.6 
BPH5 Healthy PCa Healthy 2.4 N/A N/A N/A N/A 
BPH6 Healthy PCa Healthy 5.1 Healthy PCa Healthy 4.8 
BPH7 Healthy PCa Healthy 6.9 PCa Healthy Healthy 4.2 
BPH8 Healthy PCa Healthy 3.7 N/A N/A N/A N/A 
BPH9 PCa PCa Healthy 4.3 Healthy Healthy PCa 10.5 
BPH10 Healthy PCa Healthy 5.1 Healthy PCa PCa 9.8 
BPH11 Healthy PCa Healthy 7.4 PCa PCa PCa 4.2 
BPH12 PCa PCa Healthy 3.8 Healthy Healthy Healthy 9.4 
 
Table 9. Diagnostic Utility of miR-1825 and miR-484 for Diagnosing PCa. 
Candidate Biomarker(s) Sensitivity (%) Specificity (%) 
miR-1825 60 69 
miR-484 80 19 
miR-1825 and miR-484 45 75 
miR-1825/miR-484/PSA 40 81 
PSA (Experimental/Literature) 90/86 25/33 
 
Discussion 
MicroRNAs (miRNAs) are a class of short 
(~22nt), single stranded RNA molecules that function 
as post-transcriptional regulators of gene expression 
(17). MiRNAs can regulate a variety of important bi-
ological pathways, including: cellular proliferation, 
differentiation and apoptosis (41). MiRNAs have also 
been found to play a significant role in carcinogenesis 
(18). They do so via their ability to function as regu-
lators of tumour suppressors and oncogenes (19). As a 
result of their regulatory nature, patterns of miRNA 
expression appear to be tissue and even tumour spe-
cific (42). Moreover, profiling of miRNA expression 
patterns was shown to be more useful than the 
equivalent mRNA profiles for characterizing poorly 
differentiated tumours (21). As such, miRNA expres-
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sion “signatures” are expected to offer serious poten-
tial for diagnosing and prognosing cancers of any 
provenance (20, 21). 
Understanding the pathogenesis of vi-
ral-associated HCC is important for developing effec-
tive means of prevention and treatment of this highly 
malignant form of cancer (25). Currently, the identi-
fication of a non-invasive biological biomarker that 
can be used to screen high-risk patients is urgently 
needed to enhance HCC detection, resulting in earlier 
intervention and increasing the probability of suc-
cessful treatment. Recent studies have already identi-
fied several miRNAs whose expression is deregulated 
in viral hepatitis infections and in HCC (29). Although 
important information was gathered about the hepa-
tocarcinogenic effect of these deregulated miRNAs 
and the viral-host interactions that lead to the viral 
pathogenic effect, none of these studies evaluated the 
potential of using deregulated miRNA expression 
patterns to predict the development and progression 
of HCC among high-risk HCV infected patients. 
The aim of this study was to investigate the po-
tential for using deregulation of urinary miRNAs in 
order to accurately detect PCa among BPH patients. 
Profiling of pooled miRNA expression revealed that 
several miRNAs were differentially expressed be-
tween PCa, BPH and the healthy control group. Im-
portantly, seventeen miRNAs were identified as being 
significantly deregulated among the three groups. In 
order to narrow the scope of the study, TargetScan 
and MiRanda databases were utilized for the identi-
fication of putative targets to the differentially ex-
pressed microRNAs, for the purpose of determining 
how each microRNA might be involved with cancer 
(23). This step revealed that microRNAs 1234, 1238, 
1913, 489-5p, 1825, 484 and 483-5p were possibly 
playing a definable role in the development, progres-
sion or suppression of PCa.  
Interestingly, miR-1234 (which was found to be 
down-regulated in PCa versus the pooled healthy 
control) was found to potentially regulate the Disa-
bled homolog 2-interaction protein (DAB2IP). 
DAB2IP is thought to be a tumour suppressor gene; 
and is noticeably down-regulated in a number of PCa 
cell lines (30, 31, 32). A single nucleotide polymorphic 
variant of DAB2IP (rs1571801) is reportedly associat-
ed with an aggressive phenotype in PCa (43). Aber-
rant methylation of the DAB2IP promoter region has 
also been reported as a reason for its transcriptional 
silencing in PCa and hence progression of the disease 
(31).  
Curiously, in this study’s pooled data miR-1234 
was observed to be down-regulated in PCa relative to 
the healthy control, as opposed to up-regulated as 
might have been expected if miR-1234 was acting to 
silence the translation of DAB2IP, which appears to be 
common in some PCas. When expression levels were 
assayed by RT-qPCR among individual PCa samples, 
25% actually showed up-regulation relative to the 
average healthy level. This is of course possible since 
the previously pooled samples represented an aver-
age signal for all patients. The up-regulation of 
miR-1234 that was observed among individual cancer 
samples might have been responsible for the 
down-regulation of DAB2IP. In 2003 Chen et al. (31) 
reported that down-regulation of DAB2IP in PCa was 
the result of aberrant methylation of the DAB2IP 
promoter region. Here it is proposed that the 
up-regulation of miR-1234 might be an alternative 
mechanism for the down-regulation DAB2IP. 
Of some of the other deregulated microRNAs, 
miRs 1238 and 1913 might possibly regulate: 
SAM/SH3 domain-containing protein 1 (SASH1) and 
Heparan Sulfate Proteoglycan 2 (HSPG2), respective-
ly, whereas miR-483-5p is predicted to target Seleno-
protein-O and miR-486-5p, tumour necrosis factor 
receptor (CD40). Of these targets, SASH1 and HSPG2 
are commonly affected in various cancers.  
SASH1 has previously been reported as a can-
didate tumour suppressor gene, common to breast 
cancer (33). Down-regulation of SASH1 has also been 
reported in aggressive and metastatic cancers, such 
that its down-regulation was prognostic of poor sur-
vival among breast cancer patients (33). Heparan 
Sulphate Proteoglycan-2 (HSPG2) on the other hand 
has been implicated in a variety of processes, includ-
ing: maintenance of epithelial basement membrane 
integrity, growth factor binding and signaling, cellu-
lar differentiation, angiogenesis, neuro-muscular 
function and bone development. HSPG2 can bind to 
several other basement membrane proteins including: 
laminin-1, fibronectin, nidogen, PRELP, and collagen 
IV via its core protein or heparin sulphate side-chains 
(44, 45). The loss of HSPG2 and associated basement 
membrane structure is sometimes indicative of can-
cer, as can be the case in some invasive breast cancers 
(34).  
In this study both miR-1238 and miR-1913 were 
found by PCR, to be over-expressed in 38% of the 
initial PCa samples. Their up-regulation therefore 
might potentially have been causing the 
down-regulation of their putative targets. This 
mechanism might help explain the observations of 
lower than normal levels of SASH1 and HSPG2, as 
can be observed in some cancers (33, 34). 
Another microRNA observed as deregulated by 
microarray, miR-1825, putatively targets member-1 of 
the Discoidin Domain family of Receptors (DDR1). 
This miRNA was identified as being up-regulated in 
88% of the initial PCa samples, a seemingly common 
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event. Over-expression of DDR1 has been reported in 
many epithelial-cell cancers; DDR1 therefore likely 
plays an important role in tumourigenesis (36, 37). 
DDR1 over-expression was reported to be prognostic 
of poor survival in several cohorts of patients with 
brain, breast, or lung cancers (38). Since DDR1 is a 
putative oncogene, it is proposed that miR-1825 might 
function as a tumor-suppressor by normally or in re-
sponse to cancer, inhibiting DDR1’s translation. Since 
a majority of PCa samples (88%) showed 
up-regulation of miR-1825, it is possible that these 
cancers might have developed independently of 
DDR1. It is therefore proposed that deregulation of 
miR-1825 might be a potential mechanism for the de-
regulation of DDR1, an event common to some can-
cers. 
MiR-484, another miRNA identified by micro-
array as being deregulated in PCa may regulate the 
expression of the E3 ubiquitin-protein ligase (UBR5). 
UBR5 is thought to be involved with DNA repair (46) 
and has even reportedly been associated with cancer 
progression (39). Clancy et al. reported on the 
over-expression of a potentially mutated version of 
UBR5 found in breast and ovarian cancers and whose 
deregulation was cited as a possible cause of malig-
nant progression (39). Here RT-qPCR data show a 
down-regulation in miR-484 among 75% of PCa pa-
tients. This down-regulation might even cause the 
over-expression of miR-484’s putative target, UBR5, 
possibly resulting in cancer progression. It is therefore 
being proposed that miR-484 might function as a tu-
mor-suppressor whereby its expression controls pro-
gression via the regulation of genes, such as UBR5, 
that have already been potentially associated with 
cancer progression (39). 
Based on the aforementioned trends regarding 
the observed deregulation of miRNAs among indi-
vidual PCa samples, two of the seven miRNAs were 
selected for further evaluation among BPH samples. 
Because miR-1825 was observed to be up-regulated in 
88% of the initial PCa samples and because miR-484 
was observed to be down-regulated in 75%, it was 
thought that their deregulation might have been in-
dicative of PCa. In support of this supposition, the 
putative target for miR-1825 is DDR1, a potential on-
cogene, while miR-484 potentially regulates UBR5, 
another putative oncogene. Since BPH is commonly 
misdiagnosed as PCa (12) and leads to many unnec-
essary biopsies, and because first time prostate biop-
sies can miss cancer approximately 20% of the time 
(47, 48), it became important to evaluate any potential 
biomarker in samples collected from BPH patients. 
Using RT-qPCR, the levels of both miR-1825 and 
miR-484 were evaluated in all twelve urine samples 
that were initially collected from the BPH cohort; 
none of whom had at that time yet been diagnosed 
with PCa. Data showed that (similar to the PCa sam-
ples) miR-484 was down-regulated in the majority of 
the initially collected BPH samples. Interestingly 
however, miR-1825 was only up-regulated in 25% of 
them (four BPH samples). These numbers coupled 
with the fact that prostate biopsy can occasionally 
miss PCa (47, 48) suggest that some of the BPH pa-
tients might have possibly had or been in the process 
of developing PCa; alternatively it may have been 
indicative of a lack of specificity. In order to distin-
guish between these possibilities, the medical records 
for many of the BPH patients were updated two years 
after the initial collection; as well additional urine 
samples were also collected.  
Upon assessment of miRNA expression among 
those newly collected BPH samples, miR-1845 was 
only observed to be up-regulated in 25% of the cohort. 
In addition; miR-484 was also observed to be 
down-regulated, though this time in only 50% of BPH 
samples as opposed to 100% of them. Importantly, 
coupled to these new expression levels, the updated 
medical records indicated that four of the eight BPH 
patients had been diagnosed with PCa within the last 
two years. 
By combining the original diagnoses and ex-
pression levels with the updated levels and medical 
records, the ability of miR-1845 and/or miR-484 de-
regulation to predict PCa was investigated. Towards 
this, the sensitivity and specificity of using miR-1825 
up-regulation and/or miR-484 down-regulation to 
detect PCa was calculated. This calculation revealed 
that deregulation of miR-1825 was 60% sensitive and 
69% specific for detecting PCa, whereas miR-484 de-
regulation was 80% sensitive but only 19% specific. 
When both were combined, the sensitivity and speci-
ficity was 45% and 75%, respectively. And finally, the 
sensitivity and specificity for a panel including: 
miR-1825, miR-484 and PSA (at a 4.0ng/mL cutoff) 
were 40% and 81%, respectively. 
Despite the marginal diagnostic qualities of these 
microRNAs, the sensitivity of miR-484 was on par 
with - and the specificity of all except miR-484 were 
superior to - the literature reported values for PSA 
testing (sensitivity of 86% and specificity of 33% (12). 
It is therefore proposed that these signatures might 
(with further validation) ultimately be useful for de-
tecting PCa. 
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